10 million out of 1.4 billion isn't much. Abele and Nicholas holdings of BSX stock aren't much, and don't affect the stock price much.
The reason why BSX is a POS is because they don't have any hot-shot game-changing products to drive revenue growth. A decade ago BSX was a one-hit wonder with the drug-eluting stent, but after that, it's been all downhill since then. After massive and on-going layoffs to drive growth in EPS, there isn't much left in the R&D talent pool and R&D pipeline to develop a blockbuster product. BSX will simply because a low-margin commodities company with a stock price remaining in the single digits.